EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
196
EDITION
7
PRICE
USD 4950
CODE
MCP16695
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
SELECT PLAYERS
AbbVie; Alexion; Argenx; Bluebird Bio; Bristol-Myers Squibb/Celgene; CSL Limited; FibroGen; Gilead; GlaxoSmithKline; Novartis; Pharming Group N.V.; Sanquin; Shire plc; Vertex
SEGMENTS
» Distribution Channel (Hospital Pharmacies, Independent Pharmacies) » Dosage Type (Lyophilized, Liquid/Injectable) » Drug Class (C1-Inhibitor, Kallikrein Inhibitor (Kalbitor), Selective Bradykinin B2 Receptor Antagonist (Firazyr)))
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
4. GLOBAL MARKET PERSPECTIVE |
World Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Plasma Protease C1-inhibitor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
World Current & Future Analysis for C1-Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for C1-Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for C1-Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Kallikrein Inhibitor (Kalbitor) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Kallikrein Inhibitor (Kalbitor) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Kallikrein Inhibitor (Kalbitor) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Lyophilized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Liquid/Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Liquid/Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Liquid/Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Independent Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Independent Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Independent Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
USA Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
USA Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
USA Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
CANADA |
Canada Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
Canada Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
Canada Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
JAPAN |
Japan Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
Japan Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
Japan Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
CHINA |
China Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
China Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
China Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
EUROPE |
Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
FRANCE |
France Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
France Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
France Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
GERMANY |
Germany Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
Germany Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
Germany Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
ITALY |
Italy Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
Italy Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
Italy Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
UNITED KINGDOM |
UK Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
UK Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
UK Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
REST OF EUROPE |
Rest of Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
Rest of Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
Rest of Europe Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
ASIA-PACIFIC |
Asia-Pacific Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
Asia-Pacific Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
Asia-Pacific Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
REST OF WORLD |
Rest of World Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2020 & 2027 |
Rest of World Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2020 & 2027 |
Rest of World Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2020 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 46 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com